Topic Hub
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 15 of 15 clinical reviews.
A complete caregiver guide to administering sirolimus (rapamycin) to adolescents aged 12 to 17, covering dosing, oral solution preparation, monitoring, drug interactions, and when to call the prescriber.
Read clinical reviewA clinical guide for adolescents aged 12 to 17 on sirolimus (rapamycin) preparing to move from pediatric to adult care. Covers dosing adjustments, monitoring protocols, immunosuppression continuity, and patient education strategies backed by primary evidence.
Read clinical reviewA clinician-reviewed guide covering how sirolimus affects school performance, physical activity, vaccination schedules, and daily routines for adolescents ages 12 through 17.
Read clinical reviewA clinician-reviewed guide covering how rapamycin (sirolimus) affects daily activities, physical exercise, cognitive performance, and social participation in adults aged 65 and older, with dosing context and safety data.
Read clinical reviewA clinical guide to sirolimus use in adults aged 65 and older covering pharmacokinetics, dosing, drug interactions, immunosuppression monitoring, and care-transition planning with primary-source citations.
Read clinical reviewA clinician-reviewed guide for caregivers managing rapamycin (sirolimus) in adults 65 and older: dosing schedules, drug interactions, monitoring labs, swallowing adaptations, and safety red flags.
Read clinical reviewA clinically detailed review of how rapamycin (sirolimus) affects growth, puberty, bone density, immune development, and cognition in adolescents ages 12 to 17, with dosing context, risk data, and guidance on when use is appropriate.
Read clinical reviewA clinical deep-dive into how rapamycin (sirolimus) affects adults aged 65 and older, covering mTOR biology, immune function, pharmacokinetics, longevity trial data, and practical prescribing considerations for older patients.
Read clinical reviewEverything families and clinicians need to know about transitioning young children on sirolimus (rapamycin) to adult care: dosing, monitoring, safety data, and step-by-step handoff protocols grounded in FDA labeling and published trial data.
Read clinical reviewA clinician-reviewed guide to sirolimus use in pediatric patients under age 12, covering growth, neurodevelopment, immune function, and long-term developmental outcomes with primary-source citations.
Read clinical reviewA clinical review of rapamycin (sirolimus) off-label use in adolescents aged 12 to 17, covering approved vs. Unapproved indications, dosing considerations, safety signals, and what prescribing physicians need to know before initiating therapy.
Read clinical reviewA clinician-reviewed guide to off-label rapamycin (sirolimus) use in geriatric patients aged 65+, covering dosing protocols, mechanistic rationale, trial data, risks, and monitoring requirements.
Read clinical reviewComplete caregiver guide to giving sirolimus (rapamycin) to children under 12, covering dosing, oral solution preparation, drug interactions, side-effect monitoring, and FDA-label safety requirements.
Read clinical reviewA clinician-reviewed guide covering how sirolimus (rapamycin) affects school attendance, physical activity, infection risk, and daily schedules for children under 12 on this immunosuppressant.
Read clinical reviewA clinical deep-dive into off-label sirolimus use in children under 12, covering approved vs. Unapproved indications, dosing frameworks, pharmacokinetics, and the latest trial data for conditions like PROS, LAM, and TSC.
Read clinical review